Small cell lung cancer: Clinical practice guidelines in oncology

Gregory P. Kalemkerian; Wallace Akerley; Paul Bogner; Hossein Borghaei; Laura QM Chow; Robert J. Downey; Leena Gandhi; Apar Kishor P Ganti; Ramaswamy Govindan; John C. Grecula; James Hayman; Rebecca Suk Heist; Leora Horn; Thierry Jahan; Marianna Koczywas; Billy W. Loo; Robert E. Merritt; Cesar A. Moran; Harvey B. Niell; Janis O'Malley; Jyoti D. Patel; Neal Ready; Charles M. Rudin; Charles C. Williams; Kristina Gregory; Miranda Hughes

Small cell lung cancer: Clinical practice guidelines in oncology

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura QM Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry Jahan, Marianna Koczywas, Billy W. Loo, Robert E. Merritt, Cesar A. Moran, Harvey B. Niell, Janis O'MalleyJyoti D. Patel, Neal Ready, Charles M. Rudin, Charles C. Williams, Kristina Gregory, Miranda Hughes

School of Medicine

Research output: Contribution to journal › Article › peer-review

223 Scopus citations

Abstract

Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

Original language	English (US)
Pages (from-to)	78-98
Number of pages	21
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	11
Issue number	1
State	Published - Jan 1 2013

ASJC Scopus subject areas

Oncology

Cite this

Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. QM., Downey, R. J., Gandhi, L., Ganti, A. K. P., Govindan, R., Grecula, J. C., Hayman, J., Heist, R. S., Horn, L., Jahan, T., Koczywas, M., Loo, B. W., Merritt, R. E., Moran, C. A., Niell, H. B., ... Hughes, M. (2013). Small cell lung cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 11(1), 78-98.

Kalemkerian, GP, Akerley, W, Bogner, P, Borghaei, H, Chow, LQM, Downey, RJ, Gandhi, L, Ganti, AKP, Govindan, R, Grecula, JC, Hayman, J, Heist, RS, Horn, L, Jahan, T, Koczywas, M, Loo, BW, Merritt, RE, Moran, CA, Niell, HB, O'Malley, J, Patel, JD, Ready, N, Rudin, CM, Williams, CC, Gregory, K & Hughes, M 2013, 'Small cell lung cancer: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 11, no. 1, pp. 78-98.

@article{fefb39fa65e94287bcc167a7bbd6f136,

title = "Small cell lung cancer: Clinical practice guidelines in oncology",

abstract = "Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.",

author = "Kalemkerian, {Gregory P.} and Wallace Akerley and Paul Bogner and Hossein Borghaei and Chow, {Laura QM} and Downey, {Robert J.} and Leena Gandhi and Ganti, {Apar Kishor P} and Ramaswamy Govindan and Grecula, {John C.} and James Hayman and Heist, {Rebecca Suk} and Leora Horn and Thierry Jahan and Marianna Koczywas and Loo, {Billy W.} and Merritt, {Robert E.} and Moran, {Cesar A.} and Niell, {Harvey B.} and Janis O'Malley and Patel, {Jyoti D.} and Neal Ready and Rudin, {Charles M.} and Williams, {Charles C.} and Kristina Gregory and Miranda Hughes",

year = "2013",

month = jan,

day = "1",

language = "English (US)",

volume = "11",

pages = "78--98",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "1",

}

TY - JOUR

T1 - Small cell lung cancer

T2 - Clinical practice guidelines in oncology

AU - Kalemkerian, Gregory P.

AU - Akerley, Wallace

AU - Bogner, Paul

AU - Borghaei, Hossein

AU - Chow, Laura QM

AU - Downey, Robert J.

AU - Gandhi, Leena

AU - Ganti, Apar Kishor P

AU - Govindan, Ramaswamy

AU - Grecula, John C.

AU - Hayman, James

AU - Heist, Rebecca Suk

AU - Horn, Leora

AU - Jahan, Thierry

AU - Koczywas, Marianna

AU - Loo, Billy W.

AU - Merritt, Robert E.

AU - Moran, Cesar A.

AU - Niell, Harvey B.

AU - O'Malley, Janis

AU - Patel, Jyoti D.

AU - Ready, Neal

AU - Rudin, Charles M.

AU - Williams, Charles C.

AU - Gregory, Kristina

AU - Hughes, Miranda

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

AB - Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted.

UR - http://www.scopus.com/inward/record.url?scp=84874589027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874589027&partnerID=8YFLogxK

M3 - Article

C2 - 23307984

AN - SCOPUS:84874589027

SN - 1540-1405

VL - 11

SP - 78

EP - 98

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Small cell lung cancer: Clinical practice guidelines in oncology

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this